Ad
related to: systemic lupus erythematosus therapeutic procedures in children picturesContact our dedicated support team for help e-prescribing. Complete the patient start form to begin.
- Connect with Us
Sign up to get connected with sales
representative. Get more updates.
- Important Safety Info
Visit Official HCP Website
for full product information.
- Safety & Efficacy Data
View safety and efficacy profile
assessed in clinical trials.
- Starting Treatment
Get official info and learn how to
initiate treatment. See MOA info.
- Connect with Us
Search results
Results from the WOW.Com Content Network
Childhood-onset systemic lupus erythematosus (i.e., cSLE), also termed juvenile-onset systemic lupus erythematosus, juvenile systemic lupus erythematosus, and pediatric systemic lupus erythematosus, is a form of the chronic inflammatory and autoimmune disease, systemic lupus erythematosus (i.e., SLE), that develops in individuals up to 18 years old. [1]
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β. [medical citation needed]
In systemic lupus erythematosus patients, BAFF is overexpressed, which may cause autoimmune B cell proliferation and survival. Belimumab binds to BAFF and prevents it from binding to B cells. Without BAFF, B cells commit suicide and no longer contribute to the autoimmune damage of systemic lupus erythematosus. [medical citation needed]
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Fast Track designation is designed to expedite clinical development and regulatory review timelines. Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases, including systemic lupus erythematosus; expect to report initial clinical data in 2025
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints, skin, kidneys, blood cells, heart, and lungs.
Autoimmune optic neuropathy (AON), sometimes called autoimmune optic neuritis, may be a forme fruste of systemic lupus erythematosus (SLE) associated optic neuropathy.AON is more than the presence of any optic neuritis in a patient with an autoimmune process, as it describes a relatively specific clinical syndrome.
Cutaneous vasculitis is the most common type of vasulitis amongst those with systemic lupus erythematosus. [7] The clinical presentation is variable and can include superficial ulcerations, splinter hemorrhages, panniculitis, macules, erythema with necrosis or erythematous plaques, cutaneous infarction, livedo reticularis, bullous lesions of the extremities or urticaria lesions, papulonodular ...
Ad
related to: systemic lupus erythematosus therapeutic procedures in children pictures